In the September 2018 issue of MM&M, Davin Cho, VP of commercial strategy at AllazoHealth, outlines the future of medication adherence in the feature, “’Adherence Intelligence’ is the New AI”.
Cho discusses how, even though medication non-adherence isn’t a new problem, it is one that costs the industry $188 billion per year. General solutions have not proven to be effective, and the reason for this is the lack of specificity. Advancements in technology have helped, but can still be expensive and ineffective. With AI, unique characteristics of each patient can be recognized, and in turn, resources can be optimized, and the impact of programs can be maximized.
Read the full article in the September issue.
To learn how artificial intelligence can increase the ROI of your medication adherence program, please request a demo.